Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Radioimmunoassay for Cyclic Nucleotides
19721.9k citationsCharles W. Parker et al.profile →
Radioimmunoassay Measurement of Prostaglandins E, A, and F in Human Plasma
1973405 citationsBernard M. Jaffe, Charles W. Parker et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Charles W. Parker
Since
Specialization
Citations
This map shows the geographic impact of Charles W. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles W. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles W. Parker more than expected).
Fields of papers citing papers by Charles W. Parker
This network shows the impact of papers produced by Charles W. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles W. Parker. The network helps show where Charles W. Parker may publish in the future.
Co-authorship network of co-authors of Charles W. Parker
This figure shows the co-authorship network connecting the top 25 collaborators of Charles W. Parker.
A scholar is included among the top collaborators of Charles W. Parker based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Charles W. Parker. Charles W. Parker is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Parker, Charles W.. (2013). From The Publisher. Journal of Personal Selling and Sales Management.1 indexed citations
Wahl, Richard L., Charles W. Parker, & Gordon W. Philpott. (1983). Improved radioimaging and tumor localization with monoclonal F(ab')2.. PubMed. 24(4). 316–25.185 indexed citations
Sullivan, Timothy J., Keith L. Parker, Anthony Kulczycki, & Charles W. Parker. (1976). Modulation of cyclic AMP in purified rat mast cells. III. Studies on the effects of concanavalin A and anti-IgE on cyclic AMP concentrations during histamine release.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 117(3). 713–6.69 indexed citations
11.
Sullivan, Timothy J., Keith L. Parker, William F. Stenson, & Charles W. Parker. (1975). Modulation of cyclic AMP in purified rat mast cells. I. Responses to pharmacologic, metabolic, and physical stimuli.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 114(5). 1473–9.196 indexed citations
12.
Sullivan, Timothy J., Keith L. Parker, Seth A. Eisen, & Charles W. Parker. (1975). Modulation of cyclic AMP in purified rat mast cells. II. Studies on the relationship between intracellular cyclic AMP concentrations and histamine release.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 114(5). 1480–5.83 indexed citations
13.
Parker, Charles W.. (1975). Drug Allergy. New England Journal of Medicine. 292(18). 957–960.28 indexed citations
14.
Parker, Charles W.. (1973). The immunotherapy of cancer.. PubMed. 25(2). 325–42.7 indexed citations
Jaffe, Bernard M., Jay W. Smith, William T. Newton, & Charles W. Parker. (1971). Radioimmunoassay for Prostaglandins. Science. 171(3970). 494–496.194 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.